A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute-Pancreas (Algenpantucel-L) Immunotherapy in Subjects with Surgically Resected Pancreatic Cancer

Trial Profile

A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperAcute-Pancreas (Algenpantucel-L) Immunotherapy in Subjects with Surgically Resected Pancreatic Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs Algenpantucel-L (Primary) ; Fluorouracil; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPRESS
  • Sponsors NewLink Genetics Corporation
  • Most Recent Events

    • 20 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 09 May 2016 Results published in a NewLink Genetics Corporation media release.
    • 09 May 2016 Primary endpoint (Overall survival) has not been met, according to a NewLink Genetics Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top